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scheme, prices of brand-name and generic drugs are to be set to the same level 
after the patent expires. METHODS: The data used for this study were extracted 
from the National Health Insurance Claims database. We established a monthly 
panel dataset pertaining to pharmaceutical consumption between January 2011 
and June 2013 (30 months). Proxies of market competition were considered as 
dependent variables such as price dispersion, market share of originators and 
relative ratio of utilization (originator/generics). Independent variables including 
policy effect, number of generic drugs, vintages of the first generic drugs, month 
for new generic entry and market value. RESULTS: The new pricing policy has 
resulted in no competition mechanism. Rather the policy shows more favorable 
to originators than generic drugs. Price dispersion has significantly decreased 
to 0.92 after the new pricing regulations. Market share of the originators has not 
significantly changed. However, originator-to-generic utilization ratio significantly 
increased to 6.12 (p< 0.001) after the new policy. This study offers different results 
to the government’s intention. CONCLUSIONS: Price competition cannot be suc-
cessfully achievable unless demand-side measures are combined. To lower prices, 
the bigger market share should be delivered through demand-side measures such 
as the reference pricing or compulsory substitution to lowest drugs applied in 
some European countries.
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OBJECTIVES: To approve a public price for a drug in Jordan, Jordan food and Drug 
association (JFDA) drug pricing committee ought to review the lowest price in the 
country of origin, the price of a predefined 13 countries and in KSA. In 2012, the 
evidence of cost-effectiveness (CE) was required to inform decisions of drug pricing. 
We sought to assess the role of CE studies in pricing drugs in Jordan. METHODS: A 
retrospective review of all applications submitted to the JFDA between November 
2013 to January 2015. RESULTS: The committee reviewed a total of 1,608 drug pric-
ing requests. Two hundred four were ricing new drugs, 369 were pricing local and 
international generics. The remainder was for pricing drugs previously registered in 
Jordan but renewed periodically as per policy. There was 11 enquires involving the 
use of CE studies. Applicants failed to correspond adequately to the committee and 
the committee often reconfirmed the requests more than one time. Median (IQR) 
of correspondences was 2 (3) times per case. These studies were non-comparative 
and concerning with establishing clinical efficacy. Median (IQR) ratio of the price 
proposed by applicants to the price of comparable substitute(s) was 1.7 (1.5). The 
prices were always negotiated downwards close to the price of the available sub-
stitutes. A premium price (i.e. +10% to 20%) was advocated to reward for added 
benefits such as convenience. CONCLUSIONS: The Jordanian pricing policies are 
comprehensive in responding to most of drug pricing applications. Decisions are 
straightforward with most comparisons made between drugs having similar clinical 
profiles. However, where CE evidence required there is no formal decision rules laid 
down, thus an official set of decision tools is warranted. This would include details 
of the perspective to be adopted, the comparisons to be made, form of economic 
evaluation and sources of data.
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OBJECTIVES: To compare the difference between the maximum retail price and 
tender price of brandname and generic drugs. METHODS: A large database analysis 
was used. The database was formed by merging two sub-databases, one was the 
tender prices of 94 antimicrobial drugs and circulatory system drugs collected from 
the centralized tendering of drug purchases across all the provinces(autonomous 
regions, municipality directly under the central government) of mainland China over 
the period of 2005-2013, the other was the corresponding maximum retail prices 
issued by the National Development and Reform Commission of China. The per-
centage differences between the maximum retail price and tender price (provincial 
average) was then calculated by year for antimicrobial drugs and circulatory system 
drugs, respectively. The generic-brandname ratio of the concerned percentage differ-
ences was also calculated. RESULTS: The percentage difference between maximum 
retail price and tender price for generic drugs was large, while the corresponding 
difference in brandname drugs was much smaller. The generic-brandname ratio 
of the concerned percentage differences increased from 1.7 in 2005 to 5.7 in 2013, 
except a mild decrease in 2009 and a moderate decrease in 2012. CONCLUSIONS: 
It may be the time to lift price control on drugs in China since the maximum retail 
price issued by the national government was too high as compared with tender 
price to exert effect on generic drugs, while for brandname drugs the maximum 
retail price was too close to tender price, which also consequentially diluted the 
significance of maximum retail price.  KEYWORDS: Maximum retail price; Tender 
price; Price reform; large database analysis. 
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OBJECTIVES: Canada has established Patented Medicine Prices Review Board 
(PMPRB) in 1987 with the objective of regulating prices of patented medicines sold 
in Canada to ensure prices are not excessive. When drugs’ prices meet the guide-
lines, they will be accepted; otherwise, the sponsor company will decrease them. The 
Employee Basic Medical Insurance (UEBMI) claims of Tianjin city from April 2008 
to March 2010 were used to compare the patients’ outpatient visit, total spending, 
drug spending, and OOP spending before and after the implementation of the EMP. 
The intervention group consisted of patients who visit the primary care institu-
tion which implemented EMP at least once before and after EMP and did not visit 
the control primary care institution which did not implement EMP, vice versa for 
the control group. A difference-in-difference approach was used to estimate the 
effects adjusting for patients’ socio-demographic characteristics and disease sever-
ity. Negative binomial regression was used to estimate the outpatient visit and tobit 
model was used to estimate the cost. RESULTS: Totally, 23362 patients from 49 
interventional primary care institution and 4148 patients from 42 control institution 
were involved in the study. The regression results showed that the annual patients’ 
outpatient visits (0.5%, p= 0.791) and the visits to primary care institution (0.2%, 
p= 0.951) had no change after implementing EMP compared to the control group. 
The patient’s average total spending (-0.6%, p= 0.850), drug spending (1.6%, p= 0.703) 
and OOP spending (0.4%, p= 0.883) did not change. The average total spending (2.9%, 
p= 0.443), drug spending (1.9%, p= 0.724) and OOP spending (1.2%, p= 0.722) in primary 
care institution was also not changed after implementing EMP. CONCLUSIONS: The 
EMP in Tianjin China was not associated with more outpatient visits in primary care 
institution and less medical spending, drug spending and OOP spending.
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OBJECTIVES: Beginning in 2014, the Affordable Care Act requires new health plans to 
cover essential health benefits (EHB), including pharmaceutical products, according 
to the state level benchmark plans. The objectives of this analysis were to understand 
state level variations in design of plans, access to drugs and likely impact on patient 
choice and health outcomes. METHODS: Benchmark plans for the top five states 
(i.e., FL, IL, NY, TX and CA), covering ~116 million lives, were obtained from the CMS. 
For each plan, the categories, classes and number of covered drugs was collected and 
pooled into one database. Analysis was conducted at the entire population level, state-
level and for top classes of drugs. The comments from patient groups were reviewed 
to understand the impact of EHB on patient choice and health outcomes. RESULTS: 
Benchmark plans for the top five states provide coverage of 4215 drugs belonging 
to 158 classes as defined by USP. While four states (FL, IL, NY and TX) had a similar 
number of covered drugs (median of 892 drugs), CA had a significantly lower number 
of covered drugs, amounting to 28% less than the other four states. On average, 10% 
of the drugs were in the class called “No USP Class”, highlighting the limitation of 
CMS designated USP classification system for the new plans. In CA, FL, IL, NY and 
TX there were 18, 7, 8, 11 and 8 classes, respectively, for which only 1 was covered. 
In CA, top 8 classes were identified for which patients had a 75% lower choice than 
other states, and these included indications such as Anti-Diabetics and Pain medi-
cations. CONCLUSIONS: Review of new benchmark plans shows some states can 
have a significantly lower patient choice of therapies. There is a need for new policy 
measures to ensure that all patients have equal access to new treatments.
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OBJECTIVES: Therapeutic biologic products (BLA) are produced in living cell cul-
tures or through genetic engineering of proteins. The FDA BLA definition excludes 
allergenics, blood products, cellular and gene therapy, tissue products, and vaccines. 
This study assessed trends in BLAs licensed by the FDA and the European Medicines 
Agency (EMA) in the period 1995-2014. METHODS: Regulatory information for BLAs 
was derived from the agencies webpages. We extracted data for BLAs approved 
before the establishment of the EMA licensing process from the UK Medicines and 
Healthcare products Regulatory Agency (MHRA). Insulins and some hormones that are 
approved by the FDA using the drug application system, were excluded from analysis. 
BLA were classified using the WHO anatomical therapeutic chemical classification. 
Descriptive statistics and chi-square tests were conducted in the study. RESULTS: 115 
BLA were licensed by the FDA and the EMA in the period 1995-2014. The FDA licensed 
85.2% and the EMA 73.0% of the BLAs (p< 0.0001), with 22.6% of the BLAs licensed only 
by the FDA and 14.8% by the EMA. There were 5 BLA licensed by MHRA and the FDA. 
The EMA refused to license 4 BLAs. There were 62 BLAs (53.9% of the total) licensed by 
both agencies. The FDA licensed first 79.0% of the BLAs and the EMA 21.0%. The FDA 
licensed the BLAs in a median of 181 days before than the EMA. The largest number 
of BLAs corresponded to antineoplastic and immunomodulating agents (48.7% of 
BLAs), blood and blood forming organs (13.0%), and alimentary tract and metabolism 
(9.6%). CONCLUSIONS: The study found differences in the number of BLAs licensed 
by the FDA and the EMA. The FDA approved faster and licensed significantly more 
BLAs than the EMA. Future research should evaluate the effect in patient outcomes 
and cost of differences in BLAS availability in US and Europe.
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OBJECTIVES: This study aims to evaluate the impact of the new pricing policy 
implemented as of April, 2012 in South Korea on market competition among 
off-patent drugs since the reform has taken an objective to introduce market 
competition mechanisms among off-patent drugs. According to the new pricing 
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OBJECTIVES: The Pharmacy and Therapeutics Committee (P&TC) is a policy recom-
mending and enforcing body which oversees the adoption of effective formulary 
system within the health care organization, the aim of the study is to explore the 
characteristics of P& TC in tertiary and secondary hospitals in Riyadh city, Saudi 
Arabia. METHODS: A cross-sectional survey targeted hospital pharmacy mangers 
in Riyadh city in 2014. The survey gathered information about P&TC organizational, 
communicational and functional characteristics. RESULTS: Of 30 hospital pharma-
cies, 23 (76.6%) pharmacy managers responded, 21(70%) hospitals met the inclu-
sion criteria, 15 (71.4%) are governmental and 6 (28.6%) are private hospitals. Of 21 
hospitals, 20 (95.2%) have P&T Committee. 15 (71.4%) committees have all required 
written policies and procedures that govern the committee business. The aver-
age total number of the P&T committee members is 13.5 (SD= 5), and dominated 
by physicians, pharmacists, and nurses (6.9 (SD= 3.4), 2.7(SD= 1.2), and 1.4(SD= 0.8)) 
respectively. 89.5% of these committees are chaired by physicians and 100% of them 
are coordinated by the pharmacists. Only 9 (45%) of the committees distribute the 
meeting agenda to their members 6 days or more before the meeting date. The 
average number of meetings is 12 (SD= 6) meeting per year, drug availability, for-
mulary change updates, drug safety related issues were frequently discussed in 
each meeting of 11(55%) hospital P&T committees. Formulary non adherence is less 
frequently, and prescribing guidelines is the least frequent. The average number of 
drugs deleted or added to the formulary are 6.3(SD= 5.9), 19.2 (SD= 18.9) drug per 
year, respectively. CONCLUSIONS: Adopting P&T Committee in Saudi governmental 
hospitals is a common practice, however, it considered in early stage in private hos-
pitals and more likely to be contributed to the accreditation requirements, therefore, 
more study to be done to study the quality of the committees in private hospital to 
ensure the effectiveness of formulary system.
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OBJECTIVES: To determine the influencing factors and main principles of regulatory 
and policy framework in the pharmaceutical wholesale and retail system to identify 
good practices for adaptation in Central Eastern European (CEE) countries. METHODS: 
A comprehensive literature review in the scientific and grey literature and a series of 
expert interviews were conducted to identify influencing factors in three major cat-
egories: general political, business economic and health policy principles. RESULTS: 
Regulatory and policy framework related to the pharmaceutical wholesale and retail 
system is influenced by multiple stakeholders with different interest. Health policy 
demands timely access to high quality medicines to maximise health gain for the 
population with respect to equity. Budget constraints necessitate public need for a 
sustainable and efficient pharmaceutical distribution channel. To overcome these 
constraints, pharmaceutical wholesalers and pharmacies have to improve operational 
efficiency by taking into account economies of scale/scope; or positive synergies of 
horizontal and vertical integration. According to general political objectives policy 
makers may choose from 1) regulated vs. liberalised system, 2) with monopolistic 
vs. competing wholesalers and community pharmacies 3) with national vs. interna-
tional, and 4) public vs. private ownership. Pharmacists may consider the provision 
of advanced health care services besides the traditional logistic activities to intensify 
professional influence on health policies. CONCLUSIONS: Evidence base of policy 
and regulatory framework related to pharmaceutical trade can be improved based 
on comprehensive review of scientific evidence on major principles to harmonise 
different objectives of stakeholders. However, publications with relevance to CEE and 
in general lower income countries are very limited.
PHP25
orPHan and ulTra-orPHan TecHnologies in THe new era of PaymenT 
reform: uniTed sTaTes Payer PercePTions
Hogue S.1, Brogan A.P.2, Croft E.3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI-Health Solutions, Research Triangle 
Park, NC, USA, 3RTI-Health Solutions, Manchester, UK
OBJECTIVES: To understand United States (US) payer perceptions and challenges in 
the evaluation of emerging health technologies with orphan and ultra-orphan des-
ignations. METHODS: In-depth, qualitative, one-on-one interviews were conducted 
with US payer decision makers from the RTI Health Solutions US Commercial Payer 
Advisory Panel. RESULTS: In the US, patient access to orphan and ultra-orphan 
technologies is seldom denied due to the rarity of the diseases, unmet needs, and 
lack of alternative treatments. Payers identify the biggest challenges as lack of clini-
cal and comparative efficacy data and pressures from advocacy groups, patients, 
and prescribers to fund the ever-increasing numbers of orphan and ultra-orphan 
technologies, which are often very expensive and have limited clinical evidence. 
Payers estimated that spending for orphan and ultra-orphan technologies will 
increase significantly in the next 5 years, leading to concerns over future funding 
and budgets. Payers were interested in data that could have an impact on costs, cost 
offsets, resource utilization, readmissions, and real-world outcomes in their set-
tings and patient/member populations. Payers wanted to see better-defined patient 
populations and unmet needs accompanied by well-defined treatment courses (e.g., 
when to stop treatment). Benefits of new technologies may not be captured in 
traditional health economic analyses, thus increasing uncertainty. Bridging the 
clinical evidence with other robust data will be critical, because payers will be 
passing on more risk to patients and prescribers in an effort to manage budget 
constraints. CONCLUSIONS: Payers are seeking more value-based information to 
better inform decision making in the evaluation of new orphan and ultra-orphan 
technologies. The challenge to payers lies with the value of the new technology and 
who is judging that value. Rising costs of orphan and ultra-orphan technologies will 
have more impact on market access in the future; over time there will be increasing 
resistance to high prices.
objective of this study was to assess the characteristics of the reviews performed by 
the PMPRB in the period of 1998 to 2014. METHODS: Data for all reviews performed 
by the PMPRB in the period 1998 to 2014 were derived from the PMPRB webpage. 
Descriptive analysis, and trend analysis were conducted. RESULTS: PMPRB reviewed 
a total of 1457 formulations/strengths corresponding to 689 active ingredients and 
combinations in the study period. Seventy percent of PMPRB prices were within the 
guidelines and accepted. Two percent of the prices exceeded the guidelines but did 
not trigger the criteria for commencing an investigation; however, the patentee is 
expected to decrease the price. Three percent of the National Average Transaction 
Price exceeded the Maximum Average Potential Price, which triggered the inves-
tigation criteria and the drug was reported “Under Investigation”. Four percent of 
the drug prices investigated were not excessive. One and half percent of the drug 
prices were considered excessive, and by getting to this conclusion two percent 
of patentees submitted a Voluntary Compliance Undertaking (VCU). Finally one 
and half percent of patentees did not submit a VCU and PMPRB decided that a 
patented medicine was sold at an excessive price in any market in Canada, and the 
PMPRB issued a Notice of Hearing. Drug prices that were within guidelines ranged 
from92.6% (2001 to 2004) to 95.2% (2005 to 2009) respectively. However, it decreased 
to 69.8%in 2010-2014. CONCLUSIONS: The majority of the reviews performed by 
the PMPRB concluded that the prices were not excessive.
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OBJECTIVES: At the end of 2006, there was an important reform in the Hungarian 
pharmaceutical market, including serious changes in the health insurance reimburse-
ment of medicines. The aim of our study is to analyze the changes in the Hungarian 
health insurance pharmaceutical budget between 2007-2013. METHODS: Data were 
derived from the nationwide administrative dataset of the National Health Insurance 
Fund Administration (OEP), the only health care financing agency in Hungary. We 
analyzed the changes of the health insurance pharmaceutical budget between 2007-
2013. Results are given in Hungarian Forint (HUF) and US dollars (USD). The annual 
average currency exchange rates were applied according to the data of the Central 
Bank of Hungary. RESULTS: The Hungarian pharmaceutical budget was 323.6 (2007), 
325.7 (2008), 343.2 (2009), 357.2 (2010), 376.9 (2011), 315.1 (2012) and 280.0 (2013) billion 
HUF. The average annual exchange rate between Hungarian Forint and US dollar was 
183.83 (2007), 171.80 (2008), 202.26 (2009), 208.15 (2010), 200.94 (2011), 225.37 (2012) and 
223.70 (2013), which means that Hungarian Forint significantly weakened compared 
to USD. After the changes in currency exchange rate, the Hungarian pharmaceutical 
budget measured by US dollars was 1.76 (2007), 1.90 (2008), 1.70 (2009), 1.72 (2010), 
1.88 (2011), 1.40 (2012) and 1.25 (2013) billion USD. The decrease of pharma reimburse-
ment budget from 2011 to 2013 was more significant in USD dollar (33.3 %) than in 
Hungarian Forint (25.7 %) due to the weakened Hungarian currency. CONCLUSIONS: 
Due to the reform of the whole Hungarian pharmaceutical market, the Hungarian 
health insurance pharmaceutical budget significantly changed between 2007-2013. 
This change was more remarkable in USD as the Hungarian currency weakened 
compared USD during the world economic crisis.
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OBJECTIVES: One controversial issue surrounding the Free Trade Agreement (FTA) is 
patent protection and access to medicines. The FTA necessitated changes in Peruvian 
legislation to meet requirements of the treaty. This study evaluated the impact of the 
FTA on number of brand and generic pharmaceuticals registered before and after 
the agreement and implementation of the new legislation of 2009. METHODS: Data 
from 2005 to 2013 were extracted from the database provided by the Peruvian drug 
regulatory authority, DIGEMID. The frequency and proportion of brand and generic 
products registered for the first time at DIGEMID were determined using the vari-
able ‘authorization date of first registration’. Re-registered products were determined 
using the ‘authorization and expiration date’ of registration. Products awaiting regis-
tration were determined by the variable ‘status of application’. Chi-square was used to 
assess differences in proportions. RESULTS: A total of 30,201 pharmaceutical and 913 
biologics products with a unique registration number were evaluated. The proportion 
of new registrations was 74% (n= 1789) for brand and 26% (n= 621) for generic products 
in 2005; and 80% (n= 455) for brand and 20% (n= 114) for generic products in 2013 with 
a decrease of 1,841 (76%) products after legislation. The proportion of re-registrations 
was 66% (n= 714) for brand and 34% (n= 361) for generic products in 2005 with the same 
proportions in 2013 but different frequencies (58 brand and 30 generic) with a decrease 
of 987 (92%) products after legislation. There were statistically significant differences 
between brand and generic products before and after the legislation. The proportion 
of awaiting registrations was 3 times greater for brand than for generic products 
from 2009 to 2013. CONCLUSIONS: Registration of brand products was greater than 
generic products before and after the FTA and new legislation. The frequency of new 
registrations and re-registrations decreased after 2009 but increased for products 
awaiting registration.
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